Interactions between tumor cells, stromal cells, macrophages and the extracellular matrix are pivotal to the processes of tumorigenesis, metastasis, and neovascularization Macrophages within the tumor microenvironment may facilitate cancer progression, making them intriguing targets for therapy Colony stimulating factor 1 (CSF-1) and its receptor, cFMS or CSFR1, play a central role in the development of mononuclear phagocytes, recruitment of macrophages to tumors, and differentiation and function of osteoclasts In this study, we investigate in more detail the molecular mechanisms involved in cFMS inhibition on modulation of tumor-associated macrophage function and tumor growth
Introduction

ARRY-382 displays favorable pharmacokinetics in preclinical species
ARRY-382 inhibits human osteoclast differentiation and bone resorption in vitro and blocks TNF-α production in vivo
Materials and Methods
PK/PD analysis: HEK 293 cells expressing a doxycycline-inducible cFMS construct were injected subcutaneously into female NCr nu/nu mice. Tumor bearing animals were randomized into treatment groups and administered 30 mg/kg doxycycline by oral gavage 14 hr prior to ARRY-382 treatment. Mice received a single oral dose of either vehicle or ARRY-382 and sacrificed at the indicated time point. Plasma and tumor drug concentrations were determined by LC-MS, and Western blot analysis was performed to determine phospho-cFMS/total cFMS protein levels. Results are expressed as mean ± SEM.
In vivo LPS challenge: Male Swiss-Webster mice received either a single, oral dose of ARRY-382 or vehicle 30 min prior to an intraperitoneal injection of LPS (3 µg/kg), and animals were euthanized 90 min later. Serum samples were evaluated for TNF-α concentrations by ELISA (R&D Systems) and plasma drug concentrations were determined by LC-MS. Results are expressed as mean ± SEM.
In vitro osteoclast differentiation and bone resorption analysis: Human osteoclast precursor cells (Lonza) were stimulated with 33 ng/mL M-CSF and 66 ng/mL RANKL for 7 days to induce differentiation in the presence of increasing concentrations of ARRY-382. Osteoclasts were identified by staining for the presence of tartrate-resistant acid phosphatase (TRAP;Sigma). For bone resorption determination, human osteoclast precursors were plated on a human bone plate and allowed to differentiate for 7 days in the presence of M-CSF and RANKL. On day 8, ARRY-382 was added and supernatants were collected on day 13 to evaluate calcium levels (C-telopeptide). Results are expressed as mean ± SEM.
Labeling and FACS analysis of ID8 ascites: Female CB6F1 mice were inoculated IP with 10 6 ID8 tumor cells. Upon ascites accumulation, animals received daily oral administration of 100 mg/kg ARRY-382 or vehicle for 6 days. Standard volumes of ascites fluid were aliquoted, FC-blocked and labeled for 30 minutes with (antimouse) CD11b, F4/80, CD115 (e-Bioscience) and CD204 (AbD Serotec). Cells were fixed and RBCs lysed (BD Lyse/Fix Buffer). Samples were washed and then a set volume was analyzed on a Canto II (BD Biosciences) flow cytometer. Data were analyzed with FlowJo software (TreeStar). Results are expressed as group mean (red bar) and individual animals (blue diamond). Statistical significance determined by student t-test.
In vivo tumor growth inhibition study: Female NCr nu/nu mice were implanted with slow release estrogen pellets (Innovative Research of America) then inoculated subcutaneously in the flank with 5x10 6 MCF7-AP1 mammary adenocarcinoma cells in 50% matrigel (BD Biosciences). Studies were initiated when tumors reached a minimum of 200 mm 3 at which time mice were randomized by tumor size and dosed daily by oral gavage. Tumor size (caliper) and body weight were measured on the indicated days over the course of each study. ARRY-382 was well tolerated and daily administration did not result in drug-related body weight loss exceeding 10% or death in any study. Test compound administration are displayed as indicated. Tumor measurements are expressed as group mean ± SEM (n=8/group).
Immunohistochemistry: Tumor tissue was harvested and immediately placed in formalin for preparation of paraffin embedding. F4/80 immunostaining (AbD Serotec) was performed on FFPE sections with hematoxylin counterstaining.
All animal studies were performed in accordance to IACUC guidelines and in harmony with the Guide for Laboratory Animal Care and Use.
ARRY-382 inhibits MCF7-AP1 tumor growth with an accompanying decrease F4/80 (+)-staining cells 
Summary of Results
